mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Cipla and Ethris partner for the development of mRNA-based therapies
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Subscribe To Our Newsletter & Stay Updated
